Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPD
Lists
Only you see this
Abstract
In this study, inhaled GSK2269557 had an acceptable safety profile for progression into larger studies in COPD patients. Moreover, inhalation of GSK2269557 resulted in suppression of sputum IL-8 and IL-6 levels, consistent with the known anti-inflammatory activity of a PI3Kδ inhibitor. Inhibition of inflammatory cytokines in the airway compartment may contribute to the potential therapeutic benefit of a PI3Kδ inhibitor in chronically inflamed COPD patients.
BibTeX
@inproceedings{cahn2017safety,
author = {Anthony Cahn and J. Hamblin and Malcolm Begg and Robert C. Wilson and L. Dunsire and Srividya Sriskantharajah and Mickaël Montembault and Claudia Leemereise and Laura Galinanes-Garcia and Henrik Watz and Anne‐Marie Kirsten and Rainard Fuhr and Edith M. Hessel},
title = {{Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPD}},
booktitle = {Pulmonary},
year = {2017},
doi = {10.1016/j.pupt.2017.08.008},
}Loading related content...